Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized PGI2 vs Nitroglycerine for Post-Valve Replacement Pulmonary Hypertension
NCT04594629Phase 1Unknown
- Sponsor
- Ain Shams University
- Start
- Nov 2020
- Primary completion
- May 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised trial of epoprostenol in pulmonary hypertension (PH) (2 arms), sponsored by Ain Shams University. Primary endpoint: mean pulmonary artery pressure at 4 hours. Status: unknown.
02
Drugs
epoprostenol
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT04594629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04594629.